Zepbound is a GLP-1 receptor agonist that regulates appetite and glucose metabolism. Understanding its mechanism, combined with biomarker assessment and genetic context, can help providers and patients make more informed treatment decisions.

Looking for a GLP-1 receptor agonist list? This guide names the FDA-approved compounds as of April 2026, notes the dual and investigational agents, explains how the class works and what it shares on safety, and covers the genetics upstream of every GLP-1 decision.

GLP-1 RA is shorthand for GLP-1 receptor agonist. This guide decodes the abbreviation, explains the hormone and the receptor behind it, lists the medications in the class as of April 2026, covers the shared safety profile, and shows where genetics sit upstream.

Searchers pairing GLP-1 with Mounjaro usually want the class-level picture rather than a single product: how the incretin pathway works, why Mounjaro adds a second receptor, which compounds share the family, and the genetic variables that quietly sit upstream of any decision in this space.

A class-level explainer on where Mounjaro sits among GLP-1 medications: what GLP-1 is as an incretin hormone, how receptor agonists and GIP/GLP-1 dual agonists work, which drugs belong to the class, their FDA-approved uses, shared safety, and the genetics underneath them.

Mounjaro weight-loss outcomes are widely discussed and often misrepresented in before-and-after content. This article covers what published Phase 3 trials (STEP, SURMOUNT, SCALE) report as mean outcomes, typical timeline patterns, why individual outcomes vary, and why photos are not reliable guides to expectation-setting.

Zepbound is Eli Lilly's tirzepatide brand for chronic weight management (2023) and obstructive sleep apnea (2024) — it is NOT FDA-approved for type 2 diabetes. Mounjaro is the same molecule separately approved for diabetes. This article explains the brand distinction, April 2026 cost, and the FTO, TCF7L2, and MC4R genetic architecture.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — covering 8 peptide pathways, 11 SNPs, and 9 genes including FTO, MC4R, PPARG, TCF7L2, and GIPR. This comprehensive guide explains what each insight cluster covers, which peptide pathways are analyzed, and why genetic specificity is the missing variable in most weight management decisions.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including the pathways most relevant to GLP-1 receptor signaling. This article explains what the research shows about genetics and semaglutide response, why MTHFR methylation status matters in the broader metabolic picture, and how genetic testing can help inform a smarter weight management approach.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including GLP-1 receptor signaling and GIPR response pathways. This article explains how genes like FTO, MC4R, and PPARG influence appetite, fat metabolism, and weight regulation, and why your DNA may be the most underused variable in any weight management decision.